Skip to main content
Fig. 6 | Molecular Neurodegeneration

Fig. 6

From: Parkinson mice show functional and molecular changes in the gut long before motoric disease onset

Fig. 6

Effect of A30P α-synuclein on enteric cells. For in vitro studies, myenteric plexus (MP) cells isolated from C57B6/J mice (postnatal day 2) were treated with 0.5 μM monomeric and aggregated A30P α-synuclein for 5 days in vitro. This significantly reduced the number of living cells (a) and protein gene product (PGP) 9.5-positive neurons (b, c), while the toxicity was more intense using the aggregated form. Addition of aggregated A30P α-synuclein to the MP cells resulted in a significant reduction of Nefl positive neurons (d) and significantly less synaptic vesicles (e) compared with the dopamine control, as well as in significantly more Calb2 positive neurons (f). For Nefl and Calb2 data are indicated as a ratio of Nefl and Calb2 to PGP9.5 normalized to control. Calculation of Vamp2 expressions was restricted to neuronal (class III beta tubulin (Tuj1) positive) areas. Quantitative data are expressed by means ± SD from five to seven independent experiments (N = 90 images per condition). Dopamine controls are shown in yellow, monomeric α-A30P synuclein treated cells in pink and aggregated α-A30P synuclein treated cells in green. * p < 0,05; ** p < 0,01 and *** p < 0,001 vs. dopamine control, respectively, by Student’s t test and Cohen’s d (Supplementary Table 7d) and ANOVA for grouped analyses

Back to article page